Abstract
Polo-Like Kinase-1 (PLK1) exerts its influence by affecting the progression of the cell through G2/M checkpoint. Higher levels of PLK1 promote transition of the cell phase to mitosis, thereby promoting cell proliferation. Overexpression of PLK1 mRNA has been shown to be associated with worse clinico-pathological features and patient outcomes in various cancer types, including non-small cell lung cancer (NSCLC). Reports of protein expression of PLK1 by immunohistochemistry in tumour tissue has suggested a similar trend whereby higher expression of PLK1 is associated with aggressive tumour behaviour.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
